Cargando…
Careful Scrutiny of the Evidence for Drug-Drug Interactions in Clinical Decision Support Systems Is Necessary
Autores principales: | Horn, John R., Hansten, Philip D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437417/ https://www.ncbi.nlm.nih.gov/pubmed/22050397 http://dx.doi.org/10.18553/jmcp.2011.17.9.713 |
Ejemplares similares
-
Managing clinically important drug interactions
por: Hansten, Philip D.
Publicado: (2003) -
The Underrated Risks of Tamoxifen Drug Interactions
por: Hansten, Philip D.
Publicado: (2018) -
Designing and evaluating contextualized drug–drug interaction algorithms
por: Chou, Eric, et al.
Publicado: (2021) -
Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management
por: Hansten, Philip D., et al.
Publicado: (2022) -
The RANZCP Board rejects scrutiny of decisions that affect members
por: Amos, Andrew
Publicado: (2023)